Hosted on MSN

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Q4 2025 earnings call transcript

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Q4 2025 Earnings Call Transcript February 25, 2026 Recursion Pharmaceuticals, Inc. beats earnings expectations. Reported EPS is $-0.20528, expectations ...
Seeking Alpha

Recursion Pharmaceuticals, Inc. (RXRX) Q4 2025 Earnings Call Transcript

Good morning, everyone, and thank you so much for joining us. I want to start by briefly framing where Recursion is today and its journey and evolution. Over the past decade, Recursion has built ...
Nasdaq

Recursion Pharmaceuticals (RXRX) Reports Q4 Loss, Beats Revenue Estimates

Recursion Pharmaceuticals (RXRX) came out with a quarterly loss of $0.21 per share versus the Zacks Consensus Estimate of a loss of $0.28. This compares to a loss of $0.53 per share a year ago. These ...
The Register Citizen

Recursion Pharmaceuticals: Q4 Earnings Snapshot

SALT LAKE CITY (AP) — SALT LAKE CITY (AP) — Recursion Pharmaceuticals Inc. (RXRX) on Wednesday reported a loss of $108.1 million in its fourth quarter. The Salt Lake City-based company said it had a ...
The New York Times

Silicon Valley Wants to Build A.I. That Can Improve A.I. on Its Own

Ricursive Intelligence, founded by two former Google researchers and valued at $4 billion, is among several efforts to automate the creation of artificial intelligence. Anna Goldie and Azalia ...